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Abstract 
Purpose: To prepare and characterize in situ gel-forming implants of methylprednisolone for the 
treatment of spinal cord injuries. 
Methods: In situ hydrogels of methylprednisolone were prepared by dispersing polylactide glycolic acid 
(PLGA) polymer and methylprednisolone in N-methyl-pyrrolidone solvent, and subsequent membrane 
sterilization. Hydrogels were prepared using varying concentrations of PLGA polymer. The 
physicochemical properties of hydrogels, including visual appearance, clarity, pH, viscosity, drug 
content, and in vitro drug release, were characterized. In vivo studies were performed to examine anti-
inflammatory activity (paw edema test) and in vivo motor function activity in a rat spinal injury model 
after injecting the hydrogels into rats. 
Results: The physicochemical properties of the gels were satisfactory. F1, F2, F3, and F4 formulations 
showed 99.67, 95.29, 88.89 and 88.20 % drug release, respectively, at the end of 7 days. In vivo anti-
inflammatory activity was highest for F1 (62.85 %). Motor function activity scores (arbitrary scale) for the 
F1, F2, F3 and F4 formulations were 4.82 ± 0.12, 4.70 ± 0.12, 4.68 ± 0.02, and 4.60 ± 0.05, 
respectively, and were higher (p < 0.05) for F1, F2 and F3) than for the standard (methylprednisolone, 
30 mg/kg body weight, iv; activity score, 4.59 ± 0.20). 
Conclusions: The in situ hydrogels of methylprednisolone developed may be useful for the effective 
management of spinal cord injuries in patients. However, further investigations are required to ascertain 
their suitability for clinical use. 
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Spinal cord injury (SCI) can lead to permanent 
disability and decreased life expectancy. The 
primary injury (local damage to tissues) is 
followed by secondary injuries (neuropathic pain, 
inflammation, reversible and/or irreversible 
damage to the nervous system), making SCI 
difficult to manage [1–4]. The management of 
pain and inflammation is achieved using various 
analgesics and anti-inflammatory agents, 
including opioids, non-steroidal anti-inflammatory 
drugs, muscle relaxants, and steroids [4–6]. 
 
Acute steroid administration has been reported to 
be effective as a first-line therapy, and a high 
dose of methylprednisolone (MP) immediately 
after traumatic SCI is well accepted as a 
standard treatment [6,7]. MP is a potent anti-
inflammatory glucocorticoid. It leads to significant 
recovery from primary tissue damage and 
secondary neuropathic pain and inflammation in 
SCI. MP use has been reported to significantly 
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improve motor nerve activity in cases of SCI [8–
10]. 
 
Although several studies have documented 
significant positive effects of MP (when 
administered intravenously) in SCI, many drugs 
used for the treatment of this condition cannot 
cross the blood–spinal cord barrier. Thus, neither 
oral nor intravenous delivery provides the optimal 
desired benefit of neuroprotective or 
neuroregenerative drugs. The physical 
inaccessibility of the spinal cord is usually dealt 
with using alternative measures, such as local 
epidural or intrathecal delivery (by bolus injection 
or catheter/implant insertion) [11,12]. The 
delivery of drugs to the microenvironment of the 
spinal cord through intrathecal administration in 
polymeric hydrogels and in situ has been 
reported to be promising in SCI, with advantages 
including improved safety, prolonged delivery (up 
to 4 weeks), and reduced dosage (frequency) 
[13–15]. 
 
Implants that are formed from polymeric gels or 
solutions containing drugs undergo chemical or 
physical changes to form unit implants for 
controlled drug delivery when injected into the 
body. Dunn et al [16] were pioneers in the 
development of in situ implants. Injectable in situ 
implants of antibiotics were prepared for the local 
treatment of periodontitis. These systems form 
implants in situ with changes in factors such as 
temperature, pH, ionic crosslinking, and solvent 
removal. Among the various techniques, in situ 
solvent removal systems have been investigated 
for the delivery of drugs such as leuprolide 
acetate (Luteinizing hormone releasing hormone 
or LHRH agonist) in prostate cancer 
management, using N-methyl-pyrrolidone (NMP) 
as the solvent [17,18]. 
 
The present study concerns the preparation of an 
in situ hydrogel of MP with polylactide glycolic 
acid (PLGA) using NMP as a biocompatible 
solvent (class 2 solvent in the International 
Conference on Harmonization (ICH) guidelines, 
with no inflammatory property in biological 
systems) [19]. NMP is a common organic solvent 
used in the preparation of in situ PLGA implants. 
In an in situ solvent removal system, MP is 
converted to a gel upon contact with the aqueous 
environment of biological fluids. Immediately 
after contact with the aqueous environment, the 
NMP diffuses out rapidly, leading to rapid 
polymer precipitation. This process ultimately 
results in the formation of a porous polymer 
matrix, which then slowly releases the drug [20]. 
In situ gels can be used for local and systemic 
controlled drug delivery [14,15,21–23]. Here, we 
describe the development of a polymeric in situ 
hydrogel of MP for intrathecal delivery to improve 







MP succinate, PLGA, and NMP were purchased 
from Sigma Aldrich, St. Louis, MO, USA). All 
other chemicals were of analytical grade.  
 
Preparation of polymeric hydrogels of MP 
 
The in situ solvent removal systems for polymeric 
hydrogels of MP were prepared using the 
formulae shown in Table 1. 
 
Table 1: Composition of in situ hydrogels of 1 % 
(w/w) methylprednisolone 
 
Implant PLGA  
(% w/w) 
NMP* 
F1 8 q.s. 
F2 10 q.s. 
F3 12 q.s. 
F4 14 q.s. 
* NMP (N-methyl-2-pyrrolidone) was used as the 
solvent. PLGA: polylactide glycolic acid. 
 
The polymeric solution was prepared with 
sufficient NMP to dissolve the PLGA at 50°C, 
and the solution was then cooled to room 
temperature (25°C). The required amount of drug 
was weighed accurately and then gently 
dispersed in the polymeric solution with stirring 
(200 rpm) for 30 min. After degassing, the 
resulting solution was sterilized by membrane 
filtration and then stored in a tightly closed glass 
vial (10 mL) in a vacuum desiccator. 
 
Physical characterization of the gel implants 
 
The prepared drug-loaded polymeric solutions 
were observed to evaluate clarity (visual 
inspection) and viscosity (Brookfield viscometer). 
 
Drug content determination 
 
From the vials of the formulations, 1 mL of each 
sample was transferred to a volumetric flask 
using a micropipette. To this sample, methanol 
(up to 10 mL) was added until complete 
precipitation (i.e., the upper solution became 
mostly clear). After centrifugation (1000 rpm, 20 
min), the clear supernatant sample was 
withdrawn. The withdrawn sample was analyzed 
spectrophotometrically at 246 nm after suitable 
dilution. 
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In vitro drug release studies 
 
The formulation (10 mL) was first converted to a 
hydrogel by mixing with 20 mL phosphate buffer 
(pH 7.4). Due to the removal of NMP, the 
hydrogel formed; this pre-gelled hydrogel was 
then used for the in vitro release study. The 
study was performed by keeping the pregelled 
formulation in a glass vial containing another 20 
mL phosphate buffer. The vial was kept on a 
shaker in a water bath at 37 ± 1 °C and 50 
oscillations/min. Samples (1 mL each) were 
withdrawn at predetermined intervals for 7 days. 
Each sample was replaced with an equal volume 
of fresh phosphate buffer. The samples (n = 3) 
were analyzed spectrophotometrically at 246 nm 
after suitable dilution. 
 
In vivo study protocols 
 
Healthy male Wistar rats (weighing 175 – 250 g) 
were used. The rats were kept in cages in 
standard environmental conditions of light and 
temperature. The rats were allowed free access 
to drinking water and a standard diet. All four 
formulations were used in the in vivo studies. 
The animal study protocols were approved by the 
Animal Care and Use Committee of Weifang 
Medical College, Zibo (approval ref. no. 
2514/10/2014). The in vivo studies were 
conducted in compliance with directive 
2010/63/EU on the handling of animals for 
scientific purposes. 
 
In vivo anti-inflammatory study 
 
The formulations were used in an in vivo anti-
inflammatory study using the standard 
carrageenan-induced hind rat paw edema model. 
Rats were divided into eight groups of six rats 
each (total, 48 rats). Rats in the control group 
(group I) remained untreated. In groups II–V, test 
formulations of polymeric in situ gels were 
injected (30 mg/kg body weight, ip) into the left 
hind paws of the rats. Group VI received 2 % 
indomethacin gel (standard). Paw edema was 
induced at 30 min after the injection of 0.1 mL of 
a 1 % (w/v) aqueous suspension of carrageenan 
in the left hind paw in all rats. The left hind paw 
volume was measured immediately (0 h) and at 
subsequent timepoints (0.5, 1, 2, 4, 6, 8, 10, 12, 
and 24 h) using a plethysmometer, and 
expressed as percent edema relative to the initial 
hind paw volume. Percent inhibition of edema 
was determined and taken as a measure of anti-
inflammatory activity. 
 
In vivo motor function activity 
 
In total, 42 rats were used. They were divided 
into four groups (normal control, negative control, 
standard, and test), with 6 rats each in first three 
groups and 24 rats in the test group. The test 
group was further subdivided into four groups of 
six rats each for the four formulations. All animals 
(except those in the normal control group) were 
subjected to laminectomy by inducing acute 
spinal injury via extradural 40-g-force clip 
compression for 10 s around T7 after the 
administration of thiopental sodium (40 mg/kg). A 
blank (non-medicated) polymeric solution was 
administered to normal control rats. The test 
groups received the drug-loaded polymeric in situ 
gels (30 mg/kg body weight, on the basis of 
several previous studies) i.t. near the site of the 
injury. The standard group received MP (30 
mg/kg body weight) i.v. at 30 min post-injury. The 
treatment was continued for 1 week. At the end 
of 7 days, motor functional activity was 
determined by observing the performance of rats 
in a horizontal bar experiment. The time period 
for which the rat could hold the horizontal bar (2-




Results are expressed as means ± standard 
deviations. Student’s t test was used. P values 





On visual inspection, a translucent matrix was 
formed on addition to phosphate buffer (pH 7.4). 
The prepared in situ hydrogels were transparent 
at all pHs tested. The pHs of all formulations 
were within the acceptable range (Table 2).  
 
Table 2: Physicochemical characteristics of in 
situ hydrogels of MP 
 
Hydrogel pH Drug 
content 
F1 6.2±0.12 99.02±1.02 
F2 6.3±0.02 100.10±0.28 
F3 6.3±0.12 99.97±1.20 
F4 6.4±0.14 100.01±0.14 
 
The formulations were colorless with good clarity. 
The drug content of the formulations ranged from 




The viscosity of the formulations showed 
pseudo-plastic rheology, indicated by the shear 
thinning properties of the formulations. The shear 
rate increased in direct proportion to the angular 
velocity in the pregelled formulations. The 
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polymeric solutions showed good syringeability 
and injectability, facilitating administration. The 
viscosity was dependent on the polymeric 
content of the formulations (Figure 1). 
 
In vitro drug release  
 
In vitro drug release studies were carried out for 
all formulations using phosphate buffer (pH 7.4) 
as the dissolution medium. Drug release values 
for formulations F1, F2, F3, and F4 were 99.67, 
95.29%, 88.89 and 88.20, respectively, at the 
end of 7 days (Figure 2). 
The formulation with more PLGA showed slower 
release of the drug at each timepoint, compared 
with formulations containing less PLGA. This 
effect was particularly significant in the initial 6 h 
for F3 and F4. 
 
In vivo anti-inflammatory activity 
 
The anti-inflammatory activities of all 
formulations of the polymeric in situ hydrogel of 




Figure 1: Rhelogical study of pregelled formulations of polymeric in situ hydrogel of 




Figure 2: In vitro release of pregelled formulations of polymeric in situ hydrogel of 
methylprednisolone: F1 (♦), F2 (□), F3 (∆), and F4 (×) 
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Table 3: Anti-inflammatory activity of formulations of polymeric in situ hydrogel of methylprednisolone 
in rats 
 
Animal group Anti-inflammatory activity 
Change in paw volume** 
(mL) 
Inhibition of paw 
edema (%) 
Control 1.05 ± 0.04* - 
Standard (2 % indomethacin gel) 0.41 ± 0.45 60.95 
F1 0.39 ± 0.12 a 62.85 
F2 0.40 ± 1.29 a 61.90 
F3 0.42 ± 1.21 a 60.0 
F4 0.42 ± 1.01 a 60.0 
*Mean ± SEM, n = 6; **change in paw volume 12 h after carrageenan injection; ap < 0.05 vs. control 
 
Inhibition of paw edema was used as an index 
of anti-inflammatory activity. It was highest for 
F1 (62.85 %). The rank order of activity was F1 
> F2 > F3 > F4. An in vivo study was also 
performed to assess the effectiveness of motor 
nerve activity post-trauma in Wistar rats. The F1 
group showed better recovery from spinal injury 
in terms of improved activity score. Despite 
showing lesser effects than the other two 
groups, F3 and F4 showed better activity scores 
(4.68 ± 0.02 and 4.60 ± 0.05, respectively) than 
the standard (4.59 ± 0.20; Table 4). 
 
Table 4: In vivo motor function activity of in situ 
hydrogel of methylprednisolone in a rat spinal 
injury model 
 
Group Total activity 
score* 
Control (normal) 8.10 ± 1.10 
Control (negative)       0.99 ± 1.0 
Standard (MP, i.v.) 4.59 ± 0.20 
F1 4.82 ± 0.12a 
F2 4.70 ± 0.12a 
F3 4.68 ± 0.02a 
F4 4.60 ± 0.05a 




In situ hydrogels of MP showed good drug 
content and rheological properties, and 
formulations with higher polymer concentrations 
showed greater viscosity. The higher-viscosity 
polymeric formulations showed slower in vitro 
drug release, likely due to the formation of a 
stiffer in situ gel. In situ gel stiffness is related 
positively to the height of is the diffusional barrier 
faced by the drug. Previous reports showed that 
higher concentrations of polymer delayed the 
onset of release from the formulation due to the 
retardation of polymer precipitation [22–24]. 
 
The formulations showed better in vivo 
performance, indicated by increased anti-
inflammatory activity and motor function activity 
in Wistar rats, compared with the corresponding 
standards. Formulations F1, F2, F3, and F4 
showed in vivo performance in terms of motor 
function activity according to their polymeric 
content. Those with higher polymeric content 
showed less total drug release up to day 7, so 
the effects were smaller. However, even the 
formulation with the least effect (F4) was better 
than the standard. As the aim of the study was to 
prepare a prolonged drug delivery system 
showing a desired effect in SCI, formulations F3 





Biodegradable polymers can be used in 
developing implants as in situ gels of MP for 
prolonged delivery and effective management of 
pain and inflammation in SCI. The in situ gels 
prepared from PLGA using NMP as the solvent 
showed good in vivo anti-inflammatory activity 
and effectively improved rat motor function 
activity. The formulations possessed good 
physicochemical properties and prolonged drug 
release, for up to 7 days. Thus, gel implants of 
MP may be useful as an alternative approach for 
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